Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Apeiron Biologics
Apeiron Biologics
Activities:
Research & Development
X
LinkedIn
Trending Articles
IMPACT CKD model reveals the escalating toll of chronic kidney disease
The model projects up to 125 million of the population across eight countries to suffer from chronic kidney disease by 2032
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Isospec Analytics launches biomolecular analysis technology to identify unknown molecules
The novel technology optimises the identification process of unknown molecules compared to mass analysis
Building strong foundations for a resilient and planet-friendly future
Having recently released its inaugural environmental, social and governance (ESG) report, Dr Kevin Robinson caught up with Gigi Bat-Erdene, Global ESG Program Manager at PCI...
ten23 health and Ypsomed collaborate to commercialise the YpsoDose patch injector
The partnership will bring the drug delivery device to the pharmaceutical market quicker, whilst reducing development risks
Upcoming event
Making Pharmaceuticals
23–24 April 2024 | Exhibition | Coventry, UK
See all
Related Content
Research & Development
Expanding the medicinal chemist’s toolbox
Ray Boffey, Executive Director of Medicines Research at Domainex, explains the applications and benefits of fragment-based drug discovery, fragment hit expansion and the use of flow chemistry
Research & Development
Apeiron and Domainex partner to progress drug discovery
The companies have previously collaborated on hit identification, both fragment-based and virtual screening
Pharmaceutical
APEIRON appoints Peter Llewellyn-Davies as new CFO
Research & Development
Sanofi, Evotec and Apeiron Biologics to develop novel immuno-oncology treatments
Aim to bring together complementary expertise to identify and develop potential cancer treatments
Research & Development
Evotec and Apeiron establish pain alliance
Companies will identify small molecule modulators of DREAM
Subscribe now